#3 - GW Pharmaceuticals (NASDAQ:GWPH)
GW Pharmaceuticals (NASDAQ: GWPH) - GW Pharmaceuticals is an example of how to make money from the marijuana boom without playing a pure cannabis stock. GWPH is a biopharmaceutical company that already has a product derived from cannabinoids – the chemical compounds produced by cannabis flowers that help to provide relief for various symptoms. In the case of GWPH, their products Epidiolex (to treat epilepsy) and Sativex (spasticity related to MS) are already in the pipeline. As marijuana becomes more acceptable, their products are expected to gain higher acceptance. Even consumers who may see marijuana as evil may come to recognize these drugs as a “necessary evil” and a helpful way to manage symptoms. However, investors should be prepared to exercise patience when investing in GW Pharmaceuticals. Like other early-stage drug companies, they have yet to show a profit. And with regulatory hurdles to clear, profitability may be elusive for several years. However, for investors willing to wait it out, GWPH has the potential to be a great buy-and-hold stock.
About GW Pharmaceuticals
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex.
Read More - Current Price
- $218.96
- Consensus Rating
- N/A
- Ratings Breakdown
- 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- N/A
